my community channel

 BioMS Medical Corp, says drug giant Eli Lilly and Co. has agreed to give it $10 million towards one of its trials after an independent drug safety board gave it the go-ahead.

The Edmonton-based company said that the Drug Safety Monitoring Board has done its testing of the so-called Maestro-01 trial "and has recommended that the trial continue to completion."

The trial is for a treatment for patients with secondary progressive MS.
"Based on the decision, Eli Lilly and Co. has agreed to provide the $10 million milestone payment to BioMS as part of the terms of the licensing and collaboration agreement," BioMS said Wednesday..................

For the full report please go to MSRC: MS Research News : Drugs : MBP8298